In this study, we showed that the prevalence of EGFR mutations, ALK rearrangements, and ROS1 fusion were 43.0%, 5.7%, and 1.6%, respectively, in patients with NSCLC who underwent complete resections. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.